Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ.
Yuan L, et al. Among authors: li sc, li yf, li xy.
Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x.
Nat Commun. 2023.
PMID: 37580352
Free PMC article.
Clinical Trial.